HR 7400
117th Congress
House
Health
Buy American requirements
Child health
Congressional oversight
Drug therapy
Emergency medical services and trauma care
Health care costs and insurance
Health technology, devices, supplies
Infectious and parasitic diseases
Manufacturing
Medicaid
Medicare
Poverty and welfare assistance
Prescription drugs
Public contracts and procurement
American Made Pharmaceuticals Act of 2022
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 6, 2022
Referred to the Subcommittee on Health.
Apr 5, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 5, 2022
Introduced in House
Plain-English summary
American Made Pharmaceuticals Act of 2022
This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).
The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
3